Efficacy and safety of infliximab biosimilar Inflectra® in severe sarcoidosis

Respiratory Medicine
Milou C SchimmelpenninkMarcel Veltkamp

Abstract

Infliximab, a monoclonal antibody against tumor necrosis factor alpha (TNF-α) is effective third-line therapy in severe sarcoidosis. The originator product of Infliximab, Remicade®, is expensive, limiting universal access. Recently, a less expensive biosimilar of infliximab, Inflectra®, has become available, but the efficacy and tolerability has not been studied in sarcoidosis. In this retrospective cohort study, 29 patients treated with the infliximab biosimilar Inflectra®, were analysed. Patients received Inflectra® intravenously monthly at a dose of 5 mg/kg. We measured trough levels before every infusion. Before and after 6 months of induction therapy pulmonary function and disease activity were evaluated using Standardised Uptake Value (SUV) of the 18F-fluorodeoxyglucose by positron emission tomography (18F-FDG PET), soluble interleukin-2 receptor (sIL-2R), angiotensin converting enzyme (ACE) and health-related quality of life (HRQOL). In patients with pulmonary sarcoidosis as main treatment indication (n = 15) the predicted FVC improved with 8.1%, p < 0.05. Furthermore, in the whole group HRQoL improved significantly (p < 0.001), whereas SUVmax and sIL-2R significantly reduced (p < 0.001 and p = 0.001 respectively). Hospi...Continue Reading

Citations

Jul 14, 2018·Current Opinion in Pulmonary Medicine·Vasileios KouranosSimon Walsh
Jan 12, 2019·Expert Review of Clinical Immunology·Manuel Ramos-CasalsPilar Brito-Zerón
Jul 26, 2019·Current Opinion in Pulmonary Medicine·Robert P Baughman, Athol Wells
Jul 26, 2019·Current Opinion in Pulmonary Medicine·Vasileios KouranosRakesh Sharma
Aug 1, 2019·Current Opinion in Pulmonary Medicine·Hilario NunesDominique Valeyre
Feb 1, 2020·Expert Review of Respiratory Medicine·W Ennis James, Marc A Judson
Dec 24, 2019·Expert Review of Respiratory Medicine·Aman Pande, Daniel A Culver
Mar 28, 2020·Journal of Clinical Medicine·Ruth G M Keijsers, Jan C Grutters
Jul 24, 2020·Current Opinion in Pulmonary Medicine·Jacobo SellarésRobert P Baughman
Mar 14, 2019·Current Opinion in Neurology·Mareye VoortmanRobert P Baughman
Oct 24, 2019·BMJ : British Medical Journal·Daniel A Culver, Marc A Judson
Aug 1, 2019·Current Opinion in Pulmonary Medicine·Vasileios KouranosRakesh Sharma
May 6, 2020·Therapeutics and Clinical Risk Management·Thomas El JammalPascal Sève
Aug 1, 2019·Current Opinion in Pulmonary Medicine·Robert P Baughman, Athol Wells
Jan 26, 2021·Expert Review of Clinical Pharmacology·Ogugua Ndili ObiRobert P Baughman
Dec 18, 2020·Frontiers in Medicine·Thomas El JammalPascal Sève
Dec 18, 2020·Frontiers in Immunology·Alicia K Gerke
Oct 17, 2020·Journal of the American College of Cardiology·Maria Giovanna TrivieriMarc A Judson
Jun 19, 2021·Pulmonary Therapy·Andrea S MelaniElena Bargagli
Jun 19, 2021·The European Respiratory Journal·Robert P BaughmanDaniel R Ouellette

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.

© 2022 Meta ULC. All rights reserved